Wellington Management Group
PTGX icon

Wellington Management Group’s Protagonist Therapeutics PTGX Stock Holding History

Wellington Management Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$419M Sell
3,416,781
-182,863
-5% -$19.1M 0.07% 247
2026
Q1 		$379M Buy
3,599,644
+428,221
+14% +$37.9M 0.07% 244
2025
Q4 		$277M Buy
3,171,423
+1,262,977
+66% +$103M 0.05% 314
2025
Q3 		$127M Buy
1,908,446
+870,708
+84% +$49.5M 0.02% 499
2025
Q2 		$57.4M Buy
1,037,738
+50,368
+5% +$2.42M 0.01% 649
2025
Q1 		$47.7M Buy
987,370
+47,293
+5% +$1.98M 0.01% 693
2024
Q4 		$36.3M Buy
940,077
+909,998
+3,025% +$39.7M 0.01% 800
2024
Q3 		$1.35M Buy
+30,079
New +$1.22M ﹤0.01% 1658

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group's PTGX Position: Q2 2026 in Review

Wellington Management Group reduced its Protagonist Therapeutics (PTGX) stake by 5.1% in Q2 2026, selling an estimated $19.1M and leaving 3,416,781 shares worth $419M. The position accounts for 0.07% of the portfolio, ranked #247.

Wellington Management Group first reported a position in PTGX in Q3 2024 and has held it in 8 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Wellington Management Group held 3,416,781 shares of Protagonist Therapeutics worth $419M as of Q2 2026.
  • Wellington Management Group sold 182,863 Protagonist Therapeutics shares in Q2 2026, an estimated $19.1M.
  • Protagonist Therapeutics made up 0.07% of Wellington Management Group's portfolio in Q2 2026, its #247 holding.
  • Wellington Management Group first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.